Acute Graft-versus-Host Disease (aGvHD) Pipeline 2025: Pioneering Clinical Developments by 4+ Global Leaders - DelveInsight | Featuring Equillium, Regimmune Corporation, MaaT Pharma, ReAlta Life Scien

DelveInsight's, "Acute Graft-versus-Host Disease - Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Acute Graft-versus-Host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Acute Graft-versus-Host Disease (aGvHD) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a growing need for safer and more effective therapies. DelveInsight reports that over 4 pharmaceutical and biotech companies are actively developing more than 6 therapeutic candidates targeting aGvHD. These therapies are in various stages of clinical and preclinical development, highlighting significant innovation and commitment to tackling this critical health challenge.

The "Acute Graft-versus-Host Disease Pipeline Insight 2025" report from DelveInsight provides a comprehensive strategic analysis of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. It serves as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving aGvHD therapeutics market and the innovations shaping its future.

Explore the Cutting-Edge Landscape of Acute Graft-versus-Host Disease Drug Development [https://www.delveinsight.com/report-store/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Acute Graft-versus-Host Disease Pipeline Report

DelveInsight's Acute Graft-versus-Host Disease (aGvHD) pipeline report highlights a dynamic landscape with over 4 active companies developing more than 6 therapeutic candidates for aGvHD treatment.

Key updates in 2025 include:

*
April 2025: The FDA declined Breakthrough Therapy designation for Itolizumab, pausing its development pathway in acute GVHD.

*
January 2025: The FDA approved Ryoncil for the treatment of steroid-refractory acute GVHD following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Leading companies such as Equillium, Regimmune Corporation, MaaT Pharma, ReAlta Life Sciences, and others are actively developing new therapies to enhance the aGvHD treatment landscape.

Promising pipeline candidates in various stages of development include Itolizumab, RGI-2001, and others.

Acute Graft-versus-Host Disease Overview:

Acute Graft-versus-Host Disease (aGVHD) is a serious post-transplant complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT), in which the donor's immune cells attack the recipient's tissues. It affects 35-50% of transplant patients, often targeting multiple organs.

Diagnosis is primarily clinical, though biopsies may be required to differentiate aGVHD from infections or drug-related reactions. The standard treatment involves immunosuppressive therapy, typically starting with methylprednisolone, while second-line treatments are used for steroid-refractory cases. Patients with severe (grade III/IV) aGVHD generally have poor outcomes, and approximately half may later develop chronic GVHD.

Download the Acute Graft-versus-Host Disease sample report to know in detail about the Acute Graft-versus-Host Disease treatment market [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Acute Graft-versus-Host Disease Pipeline Analysis

The Acute Graft-versus-Host Disease pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Acute Graft-versus-Host Disease Market.

*
Categorizes Acute Graft-versus-Host Disease therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Acute Graft-versus-Host Disease drugs under development based on:

*
Stage of development

*
Acute Graft-versus-Host Disease Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Acute Graft-versus-Host Disease Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Acute Graft-versus-Host Disease Licensing agreements

*
Funding and investment activities supporting future Acute Graft-versus-Host Disease market advancement.

Unlock key insights into emerging Acute Graft-versus-Host Disease therapies and market strategies here: https://www.delveinsight.com/report-store/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Acute Graft-versus-Host Disease Emerging Drugs

*
Itolizumab: Equillium

Itolizumab is an experimental monoclonal antibody in Phase III clinical trials for treating acute graft-versus-host disease (aGVHD). As a first-in-class therapy, it selectively targets the CD6-ALCAM signaling pathway, which plays a crucial role in controlling T-cell activation and migration, central to many immune-mediated inflammatory conditions.

*
RGI-2001: Regimmune Corporation

RGI-2001, developed by Regimmune Corporation, is an investigational therapy designed as a liposomal form of alpha-galactosylceramide (-GalCer). The compound interacts with CD1d, a molecule present on antigen-presenting cells and invariant natural killer T (iNKT) cells.

Acute Graft-versus-Host Disease Pipeline Therapeutic Assessment

Acute Graft-versus-Host Disease Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Acute Graft-versus-Host Disease By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Acute Graft-versus-Host Disease Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Acute Graft-versus-Host Disease Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Acute Graft-versus-Host Disease therapies and key Acute Graft-versus-Host Disease companies [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Acute Graft-versus-Host Disease Current Treatment Patterns

4. Acute Graft-versus-Host Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Acute Graft-versus-Host Disease Late-Stage Products (Phase-III)

7. Acute Graft-versus-Host Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Graft-versus-Host Disease Discontinued Products

13. Acute Graft-versus-Host Disease Product Profiles

14. Acute Graft-versus-Host Disease Key Companies

15. Acute Graft-versus-Host Disease Key Products

16. Dormant and Discontinued Products

17. Acute Graft-versus-Host Disease Unmet Needs

18. Acute Graft-versus-Host Disease Future Perspectives

19. Acute Graft-versus-Host Disease Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Acute Graft-versus-Host Disease pipeline reports offerings [https://www.delveinsight.com/report-store/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-graftversushost-disease-agvhd-pipeline-2025-pioneering-clinical-developments-by-4-global-leaders-delveinsight-featuring-equillium-regimmune-corporation-maat-pharma-realta-life-scien]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.